<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00390585</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE No. E00605</org_study_id>
    <nct_id>NCT00390585</nct_id>
  </id_info>
  <brief_title>Iodixanol vs. Iomeprol to Prevent Contrast-Induced Nephropathy After Coronary Intervention (CONTRAST)</brief_title>
  <official_title>Prospective, Randomized, Comparative Study to Evaluate the Effect of Iodixanol 320 Compared to Iomeprol 350 on Contrast Medium Induced Nephropathy in Patients With Impaired Renal Function Undergoing PCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that Iodixanol 320 is associated with a lower
      incidence of contrast-induced nephropathy (CIN) when compared with hyperosmolar contrast
      medium Iomeprol 350 in patients with impaired renal function undergoing percutaneous coronary
      interventions (PCI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Iodixanol, an iso-osmolar, dimeric, non-ionic contrast agent has been shown to reduce the
      risk of developing CIN in patients with elevated serum creatinine concentrations compared to
      low-osmolar contrast agents. However, no information is available about a potential
      protective effect of Iodixanol in patients with impaired renal function on CIN when used
      during PCI. Due to the high volume of contrast exposition, patients with impaired renal
      function are at increased risk for the development of CIN compared to patients with normal
      excretory renal function.

      The purpose of the investigation is to determine the changes of renal function in patients
      with impaired renal function receiving Iodixanol 320 or Iomeprol 350 for percutaneous
      coronary intervention.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contrast-induced nephropathy after percutaneous coronary intervention during primary hospitalization</measure>
    <time_frame>primary hospitalization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of primary hospitalization</measure>
    <time_frame>Duration of primary hospitalization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe acute kidney failure</measure>
    <time_frame>severe acute kidney failure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast-induced nephropathy six months after PCI</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality and myocardial infarction at 6 and 12 months</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">324</enrollment>
  <condition>Renal Insufficiency, Chronic</condition>
  <condition>Angioplasty, Transluminal, Percutaneous Coronary</condition>
  <condition>Coronary Arteriosclerosis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Iodixanol 320</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Iomeprol 350</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iodixanol 320</intervention_name>
    <description>Iodixanol 320 is used as contrast media while coronary intervention.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>VISIPAQUE (TM)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iomeprol 350</intervention_name>
    <description>Iomeprol 350 is used as contrast media while coronary intervention.</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Imeron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  chronic renal failure

          -  Informed, written consent

        Exclusion Criteria:

          -  Cardiogenic shock

          -  Dialysis

          -  kidney transplantation

          -  Concurrent intake of nephrotoxic medication

          -  Planned or proceeded parenteral (i.v. or i.a.) administration of iodine-containing
             contrast medium at least 7 days before/after catheterization.

          -  Contra-indications for the use of Iodixanol (e.g. allergies)

          -  Women who are known to be pregnant, who are of childbearing potential and test
             positive for pregnancy, who have given birth within the last 90 days, who are
             breastfeeding

          -  Patient's inability to fully cooperate with the study protocol.

          -  Previous enrollment in this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Schoemig, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rainer Wessely, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1. Medizinische Klinik, Klinikum rechts der Isar</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999 Mar 16;130(6):461-70.</citation>
    <PMID>10075613</PMID>
  </reference>
  <reference>
    <citation>Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998 Jul;15(7):539-53.</citation>
    <PMID>9686693</PMID>
  </reference>
  <results_reference>
    <citation>Wessely R, Koppara T, Bradaric C, Vorpahl M, Braun S, Schulz S, Mehilli J, Schömig A, Kastrati A; Contrast Media and Nephrotoxicity Following Coronary Revascularization by Angioplasty Trial Investigators. Choice of contrast medium in patients with impaired renal function undergoing percutaneous coronary intervention. Circ Cardiovasc Interv. 2009 Oct;2(5):430-7. doi: 10.1161/CIRCINTERVENTIONS.109.874933. Epub 2009 Sep 22.</citation>
    <PMID>20031753</PMID>
  </results_reference>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2006</study_first_submitted>
  <study_first_submitted_qc>October 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2006</study_first_posted>
  <last_update_submitted>March 12, 2010</last_update_submitted>
  <last_update_submitted_qc>March 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. A. Schömig</name_title>
    <organization>Deutsches Herzzentrum Munich</organization>
  </responsible_party>
  <keyword>Renal Insufficiency</keyword>
  <keyword>Angioplasty, Transluminal, Percutaneous Coronary</keyword>
  <keyword>Contrast media</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

